


PHARMACEUTICAL 2019

Neurotrope Inc. Rank 147 of 371





PHARMACEUTICAL 2019

Neurotrope Inc. Rank 147 of 371

The relative strengths and weaknesses of Neurotrope Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neurotrope Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 359% points. The greatest weakness of Neurotrope Inc. is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -96%, being 235% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	29,458
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,957
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,529
Other Liabilities	0
Other Net Income	127
Property and Equipment	21
Research and Development	4,624
Revenues	0
Selling, General and Administrative Expense	3,997

Output Variable	Value in 1000 USD
Assets	29,478
Liabilities	2,957
Expenses	11,149
Stockholders Equity	26,521
Net Income	-11,022
Comprehensive Net Income	-11,022
Economic Capital Ratio	-96%